EVR Research LP Takes Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

EVR Research LP acquired a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 378,663 shares of the company's stock, valued at approximately $1,761,000. EVR Research LP owned approximately 0.10% of GoodRx as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of GoodRx by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company's stock valued at $38,935,000 after buying an additional 460,753 shares in the last quarter. Clearbridge Investments LLC bought a new position in shares of GoodRx during the fourth quarter valued at approximately $5,863,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in GoodRx by 38.7% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,228,836 shares of the company's stock valued at $5,714,000 after purchasing an additional 342,781 shares during the last quarter. Geode Capital Management LLC boosted its stake in GoodRx by 9.1% in the fourth quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company's stock valued at $4,986,000 after acquiring an additional 89,032 shares in the last quarter. Finally, Franklin Resources Inc. purchased a new stake in shares of GoodRx during the third quarter worth about $5,675,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GDRX has been the topic of several analyst reports. Wells Fargo & Company cut their price target on GoodRx from $9.00 to $8.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. KeyCorp lowered their price objective on GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Citigroup decreased their target price on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research report on Friday, January 10th. Finally, Truist Financial decreased their target price on GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research note on Thursday, April 10th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $7.93.

GoodRx Stock Performance

Shares of NASDAQ GDRX traded up $0.02 during trading hours on Thursday, reaching $4.47. The stock had a trading volume of 302,870 shares, compared to its average volume of 1,373,305. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The business's fifty day moving average is $4.63 and its two-hundred day moving average is $5.03. GoodRx Holdings, Inc. has a twelve month low of $3.82 and a twelve month high of $9.26. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -148.83, a PEG ratio of 2.46 and a beta of 1.25.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.